Study of VTRU200 for blood cancers and solid tumors
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called VTRU200 for people with certain advanced blood cancers (like AML, MDS, and DLBCL after CAR-T therapy) and some solid tumors. It may help if standard treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older (or a child aged 6 months to 17 years for AML)
- You have a specific blood cancer (AML, high-risk MDS, DLBCL after CAR-T) or an advanced solid tumor
- Your disease has come back or hasn't responded to earlier treatments
- You are in generally good health (able to do daily activities, with adequate organ function)
- You have not had prior T-cell engaging therapy or certain other treatments within a specified time
- You do not have uncontrolled infections, severe heart/lung disease, or active other cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, RVU120, combined with venetoclax for people with AML that has come back or not responded to treatment. It may be an option if you've already tried venetoclax with another drug and it didn't work.
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
This trial tests a new treatment called UB-VV400 combined with rapamycin for people with a type of blood cancer called large B-cell lymphoma that has come back or not responded to other treatments. It aims to see if this combination can help fight the cancer.
This trial tests a new drug called TGRX-814 for people with certain blood cancers like non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndromes. It aims to see if the drug is safe and effective.
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
This study tests a new intravenous drug, TCB008, for people with acute myeloid leukemia (AML) or MDS/AML that has returned or not responded to previous treatments. The goal is to see if it is safe and if it can help control the cancer.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.